2.7.11.9	I439A/W588A	site-directed mutagenesis, the mutant shows reduced binding of serum amyloid P	722751	
2.7.11.9	additional information	construction of antisense oligonucleotide-mediated loss-of-function and synthetic mRNA-based gain-of-function mutants. The loss-of-function phenotype is linked to cell death, evident primarily in the muscle of the somites, extensive loss of myelinated tracks, and brain edema, phenotype, overview	693093	
2.7.11.9	additional information	gpbp-1-/- mice and Tg-hGPBP-1 animals do not display any obvious morphological phenotype, gpbp-1-/- mice also do not show a functional phenotype, whereas Tg-hGPBP-1 mice display reduced endurance that is not attributable to mitochondrial alterations	722724	
2.7.11.9	additional information	immobilization of Goodpasture antigen-binding protein by human serum amyloid P component binding from solution and in plasma, overview. Serum amyloid P associates in the blood with a 37-kDa GPBP fragment containing the N-terminal region and the middle domain	722751	
2.7.11.9	N460A/Y461A	site-directed mutagenesis, the mutant shows unaltered binding of serum amyloid P	722751	
2.7.11.9	P500G/A501Q	site-directed mutagenesis, the mutant binding to serum amyloid P is abolished	722751	
2.7.11.9	V498A/W499A	site-directed mutagenesis, the mutant shows unaltered binding of serum amyloid P	722751	
2.7.11.9	Y461A/F462A	site-directed mutagenesis, the mutant shows reduced binding of serum amyloid P	722751